PRMT5 and cancer: Importantly, no significant toxicities or cell death was observed in the normal guts mucosa of mice treated with MTDIA and AG-270 in contrast to those treated with PRMT5 inhibitor GSK3326595, highlighting an additional benefit of this treatment and the essential function of PRMT5 in cancers.